Eli Lilly insider-related sales: 305,000 shares planned; 875,000 sold recently

Rhea-AI Filing Summary

Eli Lilly (LLY) Form 144 notifies the market of a proposed sale of 305,000 shares of common stock through J.P. Morgan Securities, with an indicated aggregate market value of $251,753,100 and an approximate sale date of 10/02/2025. The filing shows these shares were originally acquired as a gift from the J.K. Lilly Sr. Trust (acquisition date listed as 02/10/1948) and reports prior institutional sales by Lilly Endowment Inc. totaling 875,000 shares across five trades in July–October 2025, generating about $696,456,589 in gross proceeds. The filer attests no undisclosed material adverse information.

Positive

• Filing provides transparent disclosure of a planned sale of 305,000 shares valued at $251,753,100
• Securities to be sold were acquired as a gift from the J.K. Lilly Sr. Trust, documented with acquisition dates

Negative

• Related entity Lilly Endowment sold 875,000 shares in five trades during Jul–Oct 2025, generating about $696,456,589 in gross proceeds
• Proposed sale plus recent disposals represent substantial insider-related supply that could affect near-term trading liquidity

Insights

Securities Compliance Analyst

TL;DR: Form 144 discloses a planned registered sale and recent related-party dispositions.

The filing documents a proposed sale of 305,000 Eli Lilly shares via J.P. Morgan with a stated market value of $251.8 million and confirms the shares were originally received as a gift from the J.K. Lilly Sr. Trust. It also lists five recent sales by Lilly Endowment totaling 875,000 shares and approximately $696.5 million in gross proceeds.

This is a regulatory disclosure required for resales under Rule 144 and provides transparency about insider-related selling activity; it does not itself alter company financials but is material to shareholder supply.

Equity Market Strategist

TL;DR: The disclosed selling volume is sizeable and could affect short-term liquidity/pressure on the stock.

The combined recent and proposed sales amount to 1,180,000 shares reported here and in recent filings, representing notable block dispositions by related parties in a short window. That scale of selling can be relevant to intraday or short-term trading liquidity and may be observed by market participants when assessing supply dynamics.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 383 Madison Avenue, 7th Floor New York NY 10179	305000	251753100	946456759	10/02/2025	NYSE, NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/10/1948	Gift	J.K. Lilly Sr. Trust		01/21/1937	38400000		N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Lilly Endowment Inc. 2801 North Meridian Street Indianapolis IN 46208	Eli Lilly and Company Common Stock	07/24/2025	280000	225419292
Lilly Endowment Inc. 2801 North Meridian Street Indianapolis IN 46208	Eli Lilly and Company Common Stock	09/18/2025	106626	81531976.08
Lilly Endowment Inc. 2801 North Meridian Street Indianapolis IN 46208	Eli Lilly and Company Common Stock	09/19/2025	23665	18058631.34
Lilly Endowment Inc. 2801 North Meridian Street Indianapolis IN 46208	Eli Lilly and Company Common Stock	09/30/2025	113694	86793237.85
Lilly Endowment Inc. 2801 North Meridian Street Indianapolis IN 46208	Eli Lilly and Company Common Stock	10/01/2025	351015	284653451.48

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for LLY announce?

It announces a proposed sale of 305,000 Eli Lilly shares through J.P. Morgan with an aggregate market value of $251,753,100, approx. sale date 10/02/2025.

Who acquired the shares being sold and how were they acquired?

The shares were reported as acquired by gift from the J.K. Lilly Sr. Trust, with an acquisition date shown as 02/10/1948.

Has the filer or related parties sold LLY shares recently?

Yes. Lilly Endowment Inc. sold a total of 875,000 Eli Lilly shares across five transactions in Jul–Oct 2025, generating about $696,456,589.

Through which broker will the proposed sale be executed?

The filing lists J.P. Morgan Securities LLC (383 Madison Avenue, New York) as the broker for the proposed sale.

Does the filing state any undisclosed material adverse information?

The signer represents by the notice that they do not know of any material adverse information regarding the issuer that has not been publicly disclosed.